SAS Output

10-APR-2021 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 56 51 15 8 6 0 0 02/06/2017 92 40
            51 15 8 6 0 0      
 
  S1801-Melan, Adv, Adj vs Neoadj Pembrolizumab 1 Y 1 Adjuvant Arm 556 113 57 37 23 7 1 02/15/2019 287 128
        2 Neoadjuvant Pembrolizumab   108 52 33 14 3 2      
            221 109 70 37 10 3      
 
    2 Y 3 Surgery 556 194 99 64 39 11 3 02/15/2019    
            194 99 64 39 11 3      
 
    3 Y 4 Post-Surgery Pembro 556 154 78 48 22 9 1 02/15/2019    
            154 78 48 22 9 1      
 
  S2000-MELAN, M1d/ BRAF, Enco+Bini+Nivo vs Ipil+Nivo 1 Y 1 Encorafenib/Binimetinib/Nivolu 112 2 2 2 2 0 0 01/06/2021 88 42
        2 Ipilimumab + Nivolumab   2 2 2 1 0 0      
            4 4 4 3 0 0      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   53 6 4 2 0 0 11/03/2015 275 119
            53 6 4 2 0 0      
 
    2 E Total Registrations   19 3 2 0 0 0 11/03/2015    
            19 3 2 0 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   39 3 2 0 0 0 03/25/2016 173 77
            39 3 2 0 0 0      
 
No EA6174-Merkel, Adjuvant Pembrolizumab vs Observation 1 E Total Registrations   23 14 8 5 3 2 05/01/2019 192 93
            23 14 8 5 3 2